Annual Targeted Protein Degradation Summit

The Annual Targeted Protein Degradation Summit is the premier global forum dedicated to advancing the field of targeted protein degradation (TPD) and induced proximity drugs. This summit represents a significant milestone in TPD innovation, following the recent FDA approval of Arvinas' Veppanu, which marks the first drug approval in this space. As TPD approaches a new inflection point, bolstered by a recovering market projected for 2026 and substantial upfront deals worth $15 billion involving TPD candidates, the summit aims to facilitate the clinical validation necessary to regain investor confidence and attract pharmaceutical interest. The event will gather leading experts from academia, biotech, and pharma to explore cutting-edge strategies designed to accelerate the transition from early discovery to clinical application.Participants will have the opportunity to engage with notable speakers, including Kazuteru Aoki, Vice President of Biology at FIMECS, Inc., and Hyunson Jo, Founder and CEO of Pin Therapeutics, who emphasize the importance of collaborative learning in refining protein degrader platforms. The TPD&IP Summit will cover a range of topics, including PROTACs, DACs, and molecular glues, making it an essential event for anyone looking to stay at the forefront of this rapidly evolving field. Attendees will explore various tracks focused on academic frontiers, discovery, preclinical development, translational clinical development, and the latest tools and technology, all while fostering connections through dedicated networking sessions. The summit will be held at The Westin Boston Seaport District, attracting around 350 visitors from diverse regions such as South Korea and the USA, creating a vibrant environment for discussion and collaboration in the TPD biopharma landscape.